** Trajan Group TRJ.AX jumps 8.6% to A$0.880, highest since May 27
** Stock set for its best day since March 12, if trend holds
** Life sciences products developer expects FY25 revenue to exceed upper-end of guidance at A$166.5 mln ($107.68 mln)
** Sees FY25 group EBITDA at A$15.5 mln, 8.8% below lower-end of guidance
** YTD, TRJ falls 22.1%
($1 = A$1.5463)
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.SinghChundawat@thomsonreuters.com))